Entering text into the input field will update the search result below

Vertex gets FDA nod to Kalydeco for cystic fibrosis in 4 to 6-month infants

  • The FDA has approved Vertex Pharmaceuticals' (NASDAQ:VRTX) Kalydeco (ivacaftor) for use in children with cystic fibrosis (CF) aged four months to less than six months old, with at least one cystic fibrosis transmembrane conductance regulator gene mutation, that is responsive to Kalydeco based on clinical and/or in vitro assay data.
  • Kalydeco is already approved in the U.S. and EU for the treatment of CF in patients ages six months and older
  • Vertex' three supplemental marketing applications were accepted by the FDA. Also Moderna and Vertex collaborated on gene editing therapies for CF.

Recommended For You

About VRTX Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VRTX--
Vertex Pharmaceuticals Incorporated